Insulin Glargine Injection, Solution
Product Images NDC 72572-422

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Insulin Glargine (NDC 72572-422). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civica, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Site Of Injection On Body (Image 01)

An instructional diagram showing recommended subcutaneous injection sites on the human body for insulin glargine injection. Highlighted areas include the upper arms, abdomen, and the front and sides of the thighs.*

FDA Label Image

Image-02r (Image 02r)

Illustration diagram of an Insulin Glargine injection pen showing labeled components including pen cap, cartridge holder, pen body, expiration date, dose injection button, dose window selector, cartridge, and rubber seal. Below, parts of the pen needle assembly are labeled, including outer cap, inner cap, needle, and protective seal, noting that the pen needle is not included.*

FDA Label Image

Image-03r (Image 03r)

INSULIN GLARGINE injection solution 100 units per mL in a blue prefilled pen device labeled with Civica, Inc. The label shows the proprietary and generic names and the concentration, indicating it is for subcutaneous use and prescription only.*

FDA Label Image

Image-04 (Image 04)

INSULIN GLARGINE 100 IU/mL injection pen, shown in blue with a white label displaying lot and expiration information. The pen is for subcutaneous administration and labeled by Civica, Inc.*

FDA Label Image

Image-04a (Image 04a)

An instructional illustration showing a hand holding a blue cap and pulling it away from a syringe barrel, indicating removal of the cap from the syringe tip. The syringe is prefilled and marked with measurement graduations.*

FDA Label Image

Image-05a (Image 05a)

Insulin Glargine-yfgn injection, 100 units per mL, in a clear syringe with labeled scale markings. The syringe has a yellow cap and is contained within a box labeled by Civica, Inc. for subcutaneous use and single patient use only.*

FDA Label Image

Image-06 (Image 06)

An instructional illustration showing a close-up of a vial with measurement markings and a rubber stopper, with a hand peeling off a protective cap or seal from the vial top.*

FDA Label Image

Image-07 (Image 07)

Illustration showing hands removing a protective cap from the top of a pen injector device, likely for preparing an insulin glargine injection. The image highlights the step with an upward arrow indicating the cap is being lifted off.*

FDA Label Image

Image-08 (Image 08)

An instructional illustration showing hand positioning for preparing an insulin glargine injection. It demonstrates how to hold and gently shake the insulin glargine vial or pen device before administration, indicated by directional arrows guiding the motion.*

FDA Label Image

Image-09 (Image 09)

An instructional illustration showing the removal of the outer cap from a vial or pen. A finger is shown lifting the white outer cap upwards, with an arrow indicating the direction. The text "Keep outer cap" is displayed, emphasizing to retain the cap after removal.*

FDA Label Image

Image-10 (Image 10)

An instructional diagram illustrating how to remove the inner cap from an injection pen before use. The image shows two fingers pulling the cap straight off the needle of the pen. Adjacent text reads 'Throw away inner cap,' emphasizing safe preparation steps for injection.*

FDA Label Image

Image-11 (Image 11)

Illustration showing a close-up of a dosage dial on a blue insulin pen injector. The dial displays numbers for dose settings, with an arrow indicating the direction to turn the dial for adjusting dosage. A white pen cap or knob is partially visible, held by a finger.*

FDA Label Image

Image-12 (Image 12)

An instructional illustration showing the preparation of an injection with a syringe. The image depicts a syringe being held above a vial, with an arrow indicating the direction to withdraw or prepare the solution. A close-up inset shows a detailed view of the syringe tip or needle attachment process.*

FDA Label Image

Image-13r (Image 13r)

Insulin Glargine 100 IU/mL injection, solution in a prefilled syringe by Civica, Inc. The syringe is transparent with graduated markings and has a blue label indicating the product name and strength. It is intended for subcutaneous use and labeled for single patient use only.*

FDA Label Image

Image-14r (Image 14r)

Label of INSULIN GLARGINE 100 units per mL injection solution for subcutaneous use, labeled with brand name insulin glargine-yfgn by Civica, Inc. The label includes a measurement scale and hands holding the vial for injection preparation.*

FDA Label Image

Image-15 (Image 15)

An illustration showing a close-up view of a dose selection window on an insulin pen. The number 48 is displayed prominently, indicating an example of 48 units selected for injection dosing.*

FDA Label Image

Image-16 (Image 16)

An instructional illustration showing a close-up of an insulin pen dial displaying the number 49, indicating an example selection of 49 units for injection dosing.*

FDA Label Image

Image-17 (Image 17)

An instructional illustration showing a person's hand holding a syringe pen for subcutaneous injection. The syringe tip is positioned at the skin surface with an arrow indicating the direction for injecting insulin glargine solution.*

FDA Label Image

Image-18 (Image 18)

An instructional diagram showing a hand holding an insulin pen injector. The image focuses on turning the dose selector dial at the end of the pen, with two close-up insets illustrating the proper thumb placement and direction to rotate the dial for dose adjustment.*

FDA Label Image

Image-19 (Image 19)

An instructional illustration showing a hand holding a vial with a blue label for insulin glargine injection. A clock diagram indicates a 10-second wait time, likely instructing to hold the vial in a certain position or duration before use.*

FDA Label Image

Image-20 (Image 20)

An instructional illustration showing a hand removing or placing a cap on the needle of a syringe containing injection solution. The image highlights careful handling of the syringe cap with a downward arrow indicating the direction of movement.*

FDA Label Image

Image-21 (Image 21)

An instructional illustration showing two hands preparing a vial of insulin glargine injection. The first hand is twisting the cap on the vial labeled with step 1, and an arrow indicates rotation direction. The second hand points upward with step 2, indicating pulling or lifting the cap after twisting. The image visually guides opening the vial cap for subcutaneous injection.*

FDA Label Image

Image-22 (Image 22)

An instructional illustration showing hands removing the cap from a prefilled insulin glargine injection pen. A sharps disposal container is visible nearby for safe disposal of used needles.*

FDA Label Image

Image-23 (Image 23)

An instructional illustration showing a hand removing the blue cap from a syringe prefilled with insulin glargine injection solution, 100 units/mL, intended for subcutaneous use.*

FDA Label Image

Image-24 (Image 24)

A line graph comparing glucose infusion rates (mg/kg/min) over time (hours) after subcutaneous injection of Insulin glargine and NPH insulin in 20 subjects each. The graph shows glucose infusion rates measured up to 30 hours post-injection, with Insulin glargine maintaining a more stable rate than NPH insulin, which peaks earlier and declines before 20 hours. Observation period end is marked on the time axis.*

FDA Label Image

Image-25 (Image 25)

Packaging label for Insulin Glargine-yfgn Injection, 100 units/mL (U-100) in 3 mL prefilled pens. The label shows the product is for single patient use only, intended for subcutaneous administration. Distributed by Civica, Inc. and manufactured by Biocon Biologics, Inc. The label includes instructions such as not mixing with other insulins and ensuring the solution is clear and colorless.*

FDA Label Image

Image-28 (Image 28)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.